The Antioxidant Response as a Drug Target in Diabetic Neuropathy

Authors: Vincent, Andrea M.; Edwards, James L.; Sadidi, Mahdieh; Feldman, Eva L.

Source: Current Drug Targets, Volume 9, Number 1, January 2008 , pp. 94-100(7)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.

Keywords: dorsal root ganglia; Nrf2 protein; hyperglycemia; oxidative stress; advanced glycation products

Document Type: Research article

Publication date: 2008-01-01

More about this publication?

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.